Improvement of Gene-Edited Immune Cell Manufacturing for Clinical Trials

We are collaborating with multiple labs at UCSF to establish a gene-edited immune cell clinical platform
GIGIE001_Eyquem-Research-Feature-topic1

As immunotherapeutic strategies move toward more complex engineering and multiplexed editing, there is a growing need to optimize the manufacturing of CAR-engineered cells for the clinic. Our laboratory is focused on bolstering the efficiency of CAR T cell enrichment, improving the precision of T cell editing using novel tools developed in the lab. Finally, we are expanding our technologies to other immune cells and are optimizing gene editing protocols and CAR designs for NK cells.

Selected Publications

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.
Nature 568, 112–116 (2019)
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.
Nature Medicine 25, 82–88 (2019)

Research Team

AlexisTalbot
Alexis Talbot

Postdoctoral Scholar

allison_rothrock
Allison Rothrock

Research Associate

ChrisChang
Chris Chang

MSTP Student

JosephMuldoon
Joseph Muldoon

CRI Irvington Postdoctoral Fellow

VincentAllain
Vincent Allain

Postdoctoral Scholar, UCSF / Graduate Student, University of Paris

News

Media highlights of Eyquem Lab's research.
Peptide–RNP delivery paper highlighted by Nature Reviews Bioengineering
Read More >>
Peptide–RNP delivery paper highlighted by Nature Biomedical Engineering
Read More >>
Response to Low Antigen Density Is Improved by HLA-Independent T-cell Receptors
Read More >>
CRISPR-driven CARs
Read More >>
CRISPR genome editing and immunotherapy – the early adopter
Read More >>
CRISPR gene therapy is enhancing T-cell immunotherapy treatment of cancer and treatments in people could be available within 2 to 3 years
Read More >>
Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors
Read More >>
Using CRISPR to Supercharge Cancer-Killing Immune Cells
Read More >>
AACR 2018: An off-the-shelf, dual-targeted CAR T-cell product showed promising results in preclinical studies
Read More >>
Curing Cancer with CRISPR
Read More >>
Pancreatic cancer cells digest extracellular protein
Read More >>